News Sentiment

GUTS sentiment intelligence

Fractyl Health, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 69 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.79 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+4.0% over one week, -6.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

H.C. Wainwright reiterates Buy on Fractyl Health stock at $8

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 4.0% Price confirming higher
Trend fit Trend inactive -6.7% over four weeks
Fair value -69.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 24
Neutral 38
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 12
TradingView 6
Investing.com 4
Quiver Quantitative 4
GlobeNewswire 4
Moomoo 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 22
Analyst action 10

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 69
Seeking Alpha Direct company coverage

Fractyl gains after data for Revita procedure (GUTS:NASDAQ)

Fractyl Health's stock (GUTS) rose approximately 9% after the company announced positive one-year data for its Revita procedure. The procedure significantly reduced weight regain (by about 40%) in patients with obesity who had discontinued GLP-1 therapy. This suggests Revita coul

Tone
Positive 86/100
Event
Market update
Published
15 Jul 2026 14:41
Source
Seeking Alpha
Market source Direct company coverage

Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s

Fractyl Health announced that its Revita procedure helped patients maintain a significant portion of their GLP-1-induced weight loss after discontinuing the therapy. The REMAIN-1 midpoint cohort data showed up to 84% weight retention at one year compared to 46% in the sham group,

Tone
Positive 73/100
Event
Market update
Published
15 Jul 2026 12:41
Source
Market source
GlobeNewswire Direct company coverage

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Fractyl Health announced positive one-year results from its REMAIN-1 Midpoint Cohort, demonstrating that its Revita DMR System can help patients maintain significant weight loss after discontinuing GLP-1 therapies. The study showed that Revita reduced weight regain by approximate

Tone
Positive 74/100
Event
Earnings
Published
15 Jul 2026 09:41
Source
GlobeNewswire
Stock Titan Direct company coverage

After GLP-1 drugs stop, Revita retained up to 84% of weight loss

Fractyl Health (GUTS) announced positive one-year data from its REMAIN-1 Midpoint Cohort, demonstrating that its Revita DMR System helped patients retain up to 84% of GLP-1-induced weight loss after discontinuing tirzepatide, compared to 46% for sham. The study showed Revita redu

Tone
Positive 73/100
Event
Market update
Published
15 Jul 2026 09:41
Source
Stock Titan
Stock Titan Direct company coverage

Fractyl Health (Nasdaq: GUTS) reports 1-year Revita weight maintenance data

Fractyl Health (Nasdaq: GUTS) has reported positive one-year data from its REMAIN-1 Midpoint Cohort, evaluating the Revita DMR System for maintaining weight after GLP-1 therapy discontinuation in obese adults. The data showed that a single Revita procedure significantly reduced w

Tone
Positive 71/100
Event
Market update
Published
15 Jul 2026 09:41
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Fractyl Health, Inc. – NASDAQ:GUTS

The article focuses on the "Price to book forward" financial metric for Fractyl Health, Inc. (NASDAQ: GUTS). It indicates that the company's financial data on this metric is made by humans and suggests that investors can find this information on TradingView.

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 23:46
Source
TradingView
Market source Direct company coverage

Fractyl Health (GUTS) Stock Sees Fair Value Cut As Analysts Weigh Revita Opportunity

Analysts have reassessed Fractyl Health (GUTS), significantly cutting its fair value estimate from US$7.44 to US$5.03 per share, with a new price target of US$4. This adjustment reflects renewed expectations regarding the Revita procedure's potential and the large number of GLP-1

Tone
Negative 36/100
Event
Analyst action
Published
11 Jul 2026 14:09
Source
Market source
Finviz Direct company coverage

GUTS - Fractyl Health Inc Options

This article provides a detailed financial overview of Fractyl Health Inc (GUTS), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst ratings. The company's stock closed at $0.7620 with a slight decrease, and its market

Tone
Negative 39/100
Event
Analyst action
Published
05 Jul 2026 15:09
Source
Finviz
Moomoo Direct company coverage

Fractyl Health Price Target Announced at $4.00/Share by Craig-Hallum

Craig-Hallum has initiated coverage on Fractyl Health (NASDAQ:FTYL) stock, setting a price target of $4.00 per share. This target suggests a potential upside of 11.23% from the stock's previous closing price of $3.59. The new coverage and price target come after a recent decline

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 14:40
Source
Moomoo
Investing.com Direct company coverage

Craig-Hallum initiates Fractyl Health stock coverage with buy rating

Craig-Hallum has initiated coverage on Fractyl Health Inc (NASDAQ:GUTS) with a "buy" rating and a price target of $4.00, significantly above its current stock price. The firm believes Fractyl's Revita procedure, designed for weight maintenance after GLP-1 therapy discontinuation,

Tone
Positive 70/100
Event
Analyst action
Published
02 Jul 2026 01:40
Source
Investing.com
Investing.com India Direct company coverage

Craig-Hallum initiates Fractyl Health stock coverage with buy rating By Investing.com

Craig-Hallum has initiated coverage on Fractyl Health Inc (NASDAQ:GUTS) with a buy rating and a $4.00 price target, citing its potential in developing a procedure-based approach for obesity following GLP-1 discontinuation. The firm believes Fractyl's Revita solution addresses a s

Tone
Positive 72/100
Event
Analyst action
Published
01 Jul 2026 14:10
Source
Investing.com India
Moomoo Direct company coverage

Fractyl Health Initiated at Buy by Craig-Hallum

Craig-Hallum has initiated coverage on Fractyl Health with a Buy rating. This rating suggests a positive outlook for the company's stock from the investment firm. Financial details or price targets were not included in this brief announcement.

Tone
Positive 71/100
Event
Analyst action
Published
01 Jul 2026 14:10
Source
Moomoo
Moomoo Direct company coverage

Craig-Hallum Initiates Fractyl Health at Buy With $4 Price Target

Craig-Hallum has initiated coverage on Fractyl Health with a Buy rating and a price target of $4. This new rating suggests a positive outlook on the company's stock from the investment firm.

Tone
Positive 73/100
Event
Analyst action
Published
01 Jul 2026 13:40
Source
Moomoo
TradingView Direct company coverage

Fractyl Health, Inc. Actuals & Estimates (NASDAQ:GUTS)

This article provides an overview of Fractyl Health, Inc. (NASDAQ:GUTS) stock performance, financial estimates, and analyst forecasts. It covers the current stock price, recent changes, market capitalization, and upcoming earnings dates, alongside a Q&A section addressing common

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:09
Source
TradingView
TradingView Direct company coverage

GUTS Forecast — Price Target — Prediction for 2027

The article provides a forecast for Fractyl Health, Inc. (GUTS) stock, including analyst price targets and predictions for 2027. It details recent stock performance, financial metrics like market capitalization and earnings, and technical analysis ratings. The content emphasizes

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 18:40
Source
TradingView
TradingKey Direct company coverage

Fractyl Health Inc (GUTS) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Fractyl Health Inc (GUTS), noting its current financial score of 6.75, ranking it 218 out of 388 in the Biotechnology & Medical Research industry. While the company's financial status is described as robust, its operating efficiency i

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 09:39
Source
TradingKey
TradingKey Direct company coverage

Fractyl Health Inc (GUTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Fractyl Health Inc (GUTS), covering business segments, regional revenue, and profit contribution. However, the article explicitly states that the relevant data for these breakdowns have not yet been disclose

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 22:10
Source
TradingKey
Investing.com Direct company coverage

Fractyl Health director Ajay Royan buys $19,596 in company stock

Fractyl Health director Ajay Royan purchased 23,000 shares of the company's common stock for $19,596 on June 12, 2026, increasing his direct holdings to 40,901 shares. Despite the stock gaining nearly 27% in the past week, it is down 62% over the last six months. Royan also has s

Tone
Positive 66/100
Event
Market update
Published
16 Jun 2026 07:09
Source
Investing.com
Stock Titan Direct company coverage

Fractyl Health (NASDAQ: GUTS) director adds 23,000 shares in open-market buy

Fractyl Health (NASDAQ: GUTS) director Ajay Royan purchased 23,000 shares of common stock in an open-market buy on June 12, 2026, at $0.852 per share. Following this transaction, Royan directly holds 40,901 common shares and has indirect beneficial ownership of over 6.4 million s

Tone
Positive 72/100
Event
Market update
Published
15 Jun 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

GUTS SEC Filings - Fractyl Health 10-K, 10-Q, 8-K Forms

This page provides a comprehensive list of SEC filings for Fractyl Health (GUTS), including 10-K, 10-Q, and 8-K forms, as well as insider trading disclosures. Recent filings highlight director appointments, stock option grants, and a special shareholder meeting to vote on Tranche

Tone
Negative 38/100
Event
Market update
Published
13 Jun 2026 10:40
Source
Stock Titan
Stock Titan Direct company coverage

Fractyl Health (GUTS) awards 22,500 stock options to board director

Fractyl Health (GUTS) has awarded 22,500 stock options to board director Samuel Conaway as compensation for his service. These options have an exercise price of $0.7318 per share and an expiration date of June 9, 2036. The options will vest in a single installment on the earlier

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 17:41
Source
Stock Titan
Stock Titan Direct company coverage

Fractyl Health (NASDAQ: GUTS) 2026 meeting backs board and auditor

Fractyl Health, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected three Class II directors—Ian Sheffield, Marc Elia, and Clive Meanwell—for three-year terms. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the company's inde

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 05:40
Source
Stock Titan
Investing.com Direct company coverage

Fractyl Health director William Bradley buys $50,328 in stock

Fractyl Health director William Bradley purchased 68,493 shares of the company's common stock for $50,328, increasing his direct holdings to 84,622 shares. This insider buying occurs as the stock trades near its 52-week low. Additionally, Bradley was granted 22,500 stock options

Tone
Positive 74/100
Event
Market update
Published
11 Jun 2026 21:40
Source
Investing.com
Stock Titan Direct company coverage

Fractyl Health (GUTS) director buys stock and receives 22,500 options

FRACTYL HEALTH, INC. director William Bradley reported an open-market purchase of 68,493 shares of Common Stock at approximately $0.7348 per share, increasing his direct holdings to 84,622 shares. Additionally, he received a grant of stock options for 22,500 shares with an exerci

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 21:08
Source
Stock Titan
Stock Titan Direct company coverage

Fractyl Health (NASDAQ: GUTS) director buys shares and receives options

Fractyl Health (NASDAQ: GUTS) director Ian Sheffield recently bought 35,000 shares of common stock at $0.7294 per share, bringing his direct holdings to 35,000 shares. Additionally, he was granted 22,500 stock options with an exercise price of $0.7318, set to vest in a single ins

Tone
Positive 70/100
Event
Market update
Published
11 Jun 2026 20:40
Source
Stock Titan